Evidence map›Paper›PMID 42277002›Full record

ArticleNature communications2026

Tumor-resident T cells and dendritic cells form an in situ archetype during immunotherapy response in melanoma.

Andrea Di Pietro, Lewis Au, Patrick Crock, Niko Thio, Angela Pizzolla, Thu Ngoc Nguyen, Sean Macdonald, Hugh Chalmers, Ruiqing Zhu, Alessia Airaghi and 17 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Andrea Di Pietro *Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.
Lewis Au *Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.
Patrick CrockBioinformatics, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.ORCID http://orcid.org/0009-0004-5815-099X
Niko ThioSir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.
Angela PizzollaSir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0003-2024-4144
Thu Ngoc NguyenCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Sean MacdonaldCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Hugh ChalmersCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.ORCID http://orcid.org/0009-0001-1487-0299
Ruiqing ZhuCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.ORCID http://orcid.org/0009-0000-4386-1327
Alessia AiraghiCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.ORCID http://orcid.org/0009-0002-3293-1451
Tristan Molden-HauerCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Marina BacacRoche Innovation Center, Zurich, Switzerland.
Petra SchwalieRoche Innovation Center Basel, Roche Pharma Research and Early Development, Basel, Switzerland.ORCID http://orcid.org/0000-0002-6004-8095
Ramona SchlenkerRoche Innovation Center Basel, Roche Pharma Research and Early Development, Basel, Switzerland.
Mitchell P LevesqueDepartment of Dermatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Sonia MailerSir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.
Kristy Barnes-CullenSir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.
Karen WinchSir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.
Joanna ChanDepartment of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
George Au YeungSir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0003-1128-6385
Lavinia SpainSir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.
Aparna D RaoSir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.
Shahneen SandhuSir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0002-8660-4475
David E GyorkiSir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.
Grant A McArthurSir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0001-8908-6071
Laura K MackayDepartment of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0002-8496-6632
Paul J NeesonSir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia. paul.neeson@petermac.org.ORCID http://orcid.org/0000-0002-2729-5887

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor-resident (TR) T cells, known as tissue-resident memory (TRM) T cells in mice, play a central role in melanoma immunosurveillance, yet their contribution to immune checkpoint inhibitor (ICI) therapy has not been comprehensively explored. We performed spatial and single-cell profiling on 32 metastatic melanoma lymph node samples, from treatment-naïve, ICI-resistant and ICI-responsive patients. Here we show that tumor areas in ICI-responders were enriched for both CD8

Indexed as

Dendritic CellsImmunotherapyMelanomaAnimalsCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesFemaleHumansImmune Checkpoint InhibitorsInterferon-gammaLymph NodesMaleMiceT-Cell ExhaustionTumor MicroenvironmentImmune Checkpoint InhibitorsInterferon-gamma

Identifiers

PMID42277002
PMCPMC13408351

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.